In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025. After 16 weeks of treatment, vanoglipel showed reductions in HbA1c of 0.37%, 0.41%, and 0.54% at weeks 4, 8, and 16, from a baseline of 6.99%. Vanoglipel also significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L. Additional liver-specific improvements included improved liver steatosis, reduced liver stiffness, and improved FAST and NIS-4 scores. Lastly, vanoglipel also reduced pathogenic lipids in plasma, including glycerolipids and glycerophospholipids.
